Actionable news
All posts from Actionable news
Actionable news in SRNE: Sorrento Therapeutics, Inc.,

Sorrento Therapeutics: Sorrento Expands Its Executive Management Team With

The following excerpt is from the company's SEC filing.

Appointment of Dr. Jeffrey Su as Chief Operating Officer to Lead

its in-house Bioprocess and Manufacturing Operations

SAN DIEGO, October 19, 2015 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today the addition of Jeffrey Su, Ph.D., as Executive Vice President and Chief Operating Officer. Dr. Su will be responsible for all manufacturing operations at Sorrento, including the analytical and process development laboratories, the newly constructed cGMP manufacturing facility, and all required quality systems.

I am delighted that Dr. Su will join our management team. His appointment is a key addition to meet the needs of our current corporate growth and expansion of our business and pipeline programs. Dr. Su is a highly experienced executive with a proven track record of productivity and accomplishments in biological product development and manufacturing, said Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento. He adds significant expertise in all areas of biological therapeutics development and manufacturing as well as in-depth knowledge of cGMP compliance requirements and the biologics regulatory environment. With our recent acquisition of four biosimilar/biobetter monoclonal antibodies and our internal antibody programs on track to enter clinical stage next year, Dr. Su will be a key stakeholder in these development processes. He will also lead the development efforts for all other immunotherapy products, including cellular therapies and chemically-modified proteins, such as antibody-drug conjugates, bispecific antibodies, as well as cell-internalizing antibodies and peptides.

Prior to joining Sorrento, Dr. Su was Chief Scientific and Development Officer at Cytovance Biologics Inc., a leading contract development and manufacturing company. He has successfully managed development projects involving partners in the US, Asia, Canada and Europe. Dr. Su has more than 23 years of experience in the Pharmaceutical and Biotech industry, including positions of increasing responsibility at Sanofi Pasteur, Femta Biopharmaceutical, Cancervax...